Li Chunxia

Dr. Li Chunxia


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Biomaterials
Verified
Journal Article
Closed access
MWMan Wang
Man Wang
MCMengyu Chang
Mengyu Chang
QCQing Chen
Qing Chen
DWDongmei Wang
Dongmei Wang
LCLi Chunxia
Li Chunxia
BXBengang Xing
Bengang Xing

26 October 2021 in Advanced Materials
Verified
Journal Article
Closed access
PDF file
MWMan Wang
Man Wang
MCMengyu Chang
Mengyu Chang
LCLi Chunxia
Li Chunxia
QCQing Chen
Qing Chen
ZHZhiyao Hou
Zhiyao Hou
Jun LinJun Lin
Jun Lin

26 July 2022 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PZPan Zheng
Pan Zheng
BDBinbin Ding
Binbin Ding
GZGuoqing Zhu
Guoqing Zhu
LCLi Chunxia
Li Chunxia
Jun LinJun Lin
Jun Lin

8 December 2023 in Advanced Materials
Verified
Journal Article
Closed access
LQLuying Qiao
Luying Qiao
GZGuoqing Zhu
Guoqing Zhu
TJTengfei Jiang
Tengfei Jiang
YQYanrong Qian
Yanrong Qian
QSQianqian Sun
Qianqian Sun
LCLi Chunxia
Li Chunxia

1 November 2019 in Nanoscale
Verified
Journal Article
Closed access
PDF file
LGLihua Gao
Lihua Gao
QCQing Chen
Qing Chen
TGTingting Gong
Tingting Gong
JLJianhua Liu
Jianhua Liu
LCLi Chunxia
Li Chunxia
In this review, the recent advancement of ZIF-8 as nanocarriers for the loading of various therapeutic molecules to fabricate multifunctional nanoformulations for synergistic cancer therapy will be summarized.

25 September 2022 in Advanced Science
Verified
Journal Article
Open access
MWMan Wang
Man Wang
MCMengyu Chang
Mengyu Chang
PZPan Zheng
Pan Zheng
QSQianqian Sun
Qianqian Sun
GWGuangqiang Wang
Guangqiang Wang
LCLi Chunxia
Li Chunxia
Notwithstanding immune checkpoint blocking (ICB) therapy has made eminent clinical breakthroughs, overcoming immunologically “cold” tumors remains challenging. Here, a cascade potentiated nanomodulator AuPtAg‐GOx is engineered for boosting immune responsiveness. Upon 1064 nm laser irradiation, AuPtAg‐mediated mild photothermal therapy (PTT) activates cytotoxic T lymphocytes and reverses the immunogenic “cold” tumor microenvironment. Further, to amplify the thermal sensitivity of tumor cells, glucose oxidase (GOx) is introduced to suppress the production of heat shock proteins, thereby promoting mild photothermal therapy. Complementarily, AuPtAg nanozymes with catalase‐like activity can ameliorate tumor hypoxia, significantly improving the GOx activity. As a result, the combination of AuPtAg‐GOx with self‐augmented photothermal ability and PD‐L1 antibody can further escalate the antitumor efficacy. The AuPtAg‐GOx‐based synergistic starvation therapy, mild PTT, and immunotherapy cascade enhancement therapy strategy can be a favorable tool to effectively kill cancer cells.